Skip to main content
Robert Andtbacka, MD, General Surgery, Salt Lake City, UT, University of Utah Health

RobertHAndtbackaMDFACS, FRCSC

General Surgery • Salt Lake City, UT

Melanoma, Surgical Oncology (Other than Breast)

Associate Professor, Surgery, University of Utah School of Medicine

Join to view full profile

Dr. Andtbacka is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Andtbacka's full profile

Already have an account?

Education & Training

  • McGill University Faculty of Medicine
    McGill University Faculty of MedicineClass of 1997

Certifications & Licensure

  • UT State Medical License
    UT State Medical License 2006 - 2026
  • TX State Medical License
    TX State Medical License 2003 - 2025
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT)  
    Robert Andtbacka, MD, Annals of Oncology

Press Mentions

  • Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 Dual Agonist BDB001 in Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors
    Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 Dual Agonist BDB001 in Anti-PD-1 / Anti-PD-L1 Refractory Solid TumorsSeptember 7th, 2021
  • Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 Dual Agonist BDB018 in Advanced Solid Tumors
    Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 Dual Agonist BDB018 in Advanced Solid TumorsJune 23rd, 2021
  • Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual Meeting
    Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual MeetingJune 7th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Robert Andtbacka, Dr. Robert Andtbacka, MD, Dr. R Andtbacka, Dr. Robert H Andtbacka